* Announced new results from its ongoing phase 1/2
GBT440-001 study in sickle cell disease
The post BRIEF-Global Blood Therapeutics says phase 1/2 data supports hypothesis that GBT440 inhibits sickle hemoglobin appeared first on NASDAQ.
Forex – financial instrument.Forex news
* Announced new results from its ongoing phase 1/2
GBT440-001 study in sickle cell disease
The post BRIEF-Global Blood Therapeutics says phase 1/2 data supports hypothesis that GBT440 inhibits sickle hemoglobin appeared first on NASDAQ.